Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2,202
Change Today 0.00 / 0.00%
Volume 0.0
INTP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Tel Aviv
As of 10:24 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

intec pharma ltd (INTP) Snapshot

Open
$2,120
Previous Close
$2,230
Day High
$2,324
Day Low
$2,120
52 Week High
10/28/14 - $3,695
52 Week Low
12/29/14 - $1,750
Market Cap
234.2M
Average Volume 10 Days
18.0K
EPS TTM
$-4.13
Shares Outstanding
10.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTEC PHARMA LTD (INTP)

Related News

No related news articles were found.

intec pharma ltd (INTP) Related Businessweek News

No Related Businessweek News Found

intec pharma ltd (INTP) Details

Intec Pharma Ltd., a drug development company, develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill, in Israel. The Accordion Pill, a novel gastro-retentive delivery system improves the pharmacokinetics and pharmacodynamics of various drugs. The company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill – Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Intec Pharma Ltd. is based in Jerusalem, Israel.

intec pharma ltd (INTP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 764.0K
Co-Founder and Chairman
Total Annual Compensation: 767.5K
Chief Financial Officer
Total Annual Compensation: --
Executive Vice President of Research & Develo...
Total Annual Compensation: 758.6K
Vice President of Business Development and Cl...
Total Annual Compensation: 646.5K
Compensation as of Fiscal Year 2014.

intec pharma ltd (INTP) Key Developments

Intec Pharma Ltd. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Intec Pharma Ltd. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss of ILS 3,894,000 compared to ILS 4,532,000 a year ago. Financial income was ILS 816,000 compared to ILS 3,057,000 a year ago. Financial income, net was ILS 477,000 compared to ILS 2,948,000 a year ago. Loss and comprehensive loss was ILS 3,417,000 or ILS 0.62 per basic and diluted share compared to ILS 1,584,000 or ILS 0.34 per basic and diluted share a year ago. Net cash used in operating activities was ILS 6,411,000 compared to ILS 3,032,000 a year ago. Purchase of property and equipment was ILS 910,000 compared to ILS 99,000 a year ago. For the six months, the company reported operating loss of ILS 11,673,000 compared to ILS 9,823,000 a year ago. Financial income was ILS 1,412,000 compared to ILS 3,539,000 a year ago. Financial income, net was ILS 737,000 compared to ILS 3,402,000 a year ago. Loss and comprehensive loss was ILS 10,936,000 or ILS 2.0 per basic and diluted share compared to ILS 6,421,000 or ILS 1.39 per basic and diluted share a year ago. Net cash used in operating activities was ILS 13,254,000 compared to ILS 7,459,000 a year ago. Purchase of property and equipment was ILS 3,267,000 compared to ILS 247,000 a year ago.

Intec Pharma Ltd.(NasdaqCM:NTEC) added to NASDAQ Composite Index

Intec Pharma Ltd. has been added to Nasdaq Composite Index.

Intec Pharma Ltd., Special/Extraordinary Shareholders Meeting, Jul 16, 2015

Intec Pharma Ltd., Special/Extraordinary Shareholders Meeting, Jul 16, 2015., at 11:00 Israel Standard Time.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INTP:IT 2,202.00 0.00

INTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INTP.
View Industry Companies
 

Industry Analysis

INTP

Industry Average

Valuation INTP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEC PHARMA LTD, please visit www.intecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.